Eupraxia Pharmaceuticals (TSE:EPRX) has released an update.
Eupraxia Pharmaceuticals reported advances in its clinical trials and financial results for the third quarter of 2024, including positive data from their RESOLVE and SPRINGBOARD trials. The company also secured C$44.5 million in funding and strengthened its management team, despite a net loss of $6.0 million.
For further insights into TSE:EPRX stock, check out TipRanks’ Stock Analysis page.
